ABSTRACT
Introduction Reactions to drugs are common and are often an extension of their pharmacological response. The regulatory agencies approve drugs for use in humans based on an analysis of the risk-benet ratio that changes signicantly depending on the treatment modality. A drug used for treating soft-tissue malignancy may be allowed with the much higher potential of both adverse reactions and side effects than for a product used for analgesia.
